“o.itemList.length” “this.config.text.ariaShown”
“This.config.text.ariaFermé”
AstraZeneca Plc (NYSE: AZN) announced Monday that its COVID-19 vaccine candidate is entering Phase 3 clinical trials for all adult teams in the United States.
What happened: The progression of AZD1222 is already in the final stages of testing in the UK, Brazil and South Africa, with long-term testing planned in Japan and Russia.
The company recruits up to 30,000 other people in the United States, over the age of 18, to verify the safety, efficacy and immunogenicity of the vaccine in the prevention of COVID-19.Collectively, the company expects more than 50,000 participants worldwide.
In addition, the British biopharmaceutical company estimates a global source capacity of approximately 3 billion doses of vaccine.
Why it’s important: the US trial is important. But it’s not the first time It is supported by the Advanced Biomedical Development Authority (BARDA), a segment of the U.S. Undersecretary of Health and Health Decompensant (HHS), and the U.S.But it’s not the first time For the Office of Preparedness and Intervention (HHS), and the Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. National Institute of Health, the U.S. Institute of Health, and the U.S. Institute of Health.But it’s not the first time
BARDA provided $1 billion to the company in May 2020 for the vaccine.
FDA President Stephen Hahn told the Financial Times that the regulator is in a position to grant an emergency use authorization to a vaccine candidate before the effects of the third phase clinical trials become available.
AstraZeneca’s COVID-19 vaccine may obtain such approval until October, according to FT.
Applicants for the Moderna Inc. coronavirus vaccine.(NASDAQ: MRNA) and Pfizer Inc.(NYSE: PFE) are also undergoing complex clinical trials in the United States.
Price action: At the end of extended trading hours, AZN shares rose 0.89% to $56.50.
Meet Benzinga
FDA leader says COVID-19 vaccine could get emergency approval without the effects of Phase 3: FT trial
© 2020 Benzinga.com.Benzinga offers investment advice All rights are reserved.